Analyst Reco. Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
23.26 ^USD	-3.92%		-4.55%	+7.78%

May. 30	Castle Biosciences, Inc. Announces to Present New Data Related to Its DecisionDx-Melanoma and DecisionDx-UM Tests At the 2024 American Society of Clinical Oncology	CI
May. 29	Castle Biosciences, Inc. Announces That New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Castle Biosciences Insider Sold Shares Worth $574,679, According to a Recent SEC Filing	May. 08	MT
Castle Biosciences Insider Sold Shares Worth $441,853, According to a Recent SEC Filing	Apr. 08	MT
Guggenheim Initiates Castle Biosciences With Buy Rating, $25 Price Target	Dec. 14	MT
Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder	Nov. 08	CI
KeyBanc Adjusts Price Target on Castle Biosciences to $25 From $37, Maintains Overweight Rating	23-08-04	MT
BTIG Research Adjusts Castle Biosciences Price Target to $30 From $38, Maintains Buy Rating	23-06-15	MT
Scotiabank Adjusts Castle Biosciences Price Target to $33 From $54, Maintains Sector Outperform Rating	23-06-06	MT
Canaccord Genuity Adjusts Price Target on Castle Biosciences to $40 From $60, Keeps Buy Rating	23-06-06	MT
SVB Securities Adjusts Price Target on Castle Biosciences to $35 From $50, Maintains Outperform Rating	23-06-05	MT
Lake Street Adjusts Castle Biosciences' Price Target to $32 From $41, Keeps Buy Rating	23-06-05	MT
Baird Adjusts Castle Biosciences Price Target to $25 From $35, Maintains Outperform Rating	23-06-05	MT
KeyBanc Adjusts Price Target on Castle Biosciences to $37 From $40, Maintains Overweight Rating	23-05-05	MT
Baird Adjusts Price Target on Castle Biosciences to $35 From $38, Maintains Outperform Rating	23-05-04	MT
Baird Adjusts Price Target on Castle Biosciences to $38 From $42, Maintains Outperform Rating	23-03-01	MT
Scotiabank Initiates Castle Biosciences at Sector Outperform With $54 Price Target	23-01-05	MT
Baird Adjusts Castle Biosciences' Price Target to $41 From $48, Keeps Outperform Rating	22-11-03	MT
SVB Securities Adjusts Castle Biosciences' Price Target to $50 from $45, Keeps Market Outperform Rating	22-08-09	MT
Baird Adjusts Castle Biosciences' Price Target to $48 From $44, Maintains Outperform Rating	22-08-09	MT
KeyBanc Adjusts Castle Biosciences' Price Target to $40 from $90, Keeps Overweight Rating	22-05-11	MT
SVB Securities Adjusts Castle Biosciences' Price Target to $45 from $65, Keeps Outperform Rating	22-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Castle Biosciences, Inc.

Equities

CSTL

US14843C1053

Analyst Reco.

Filters